rpl701 Antibody

What is RPL7 and why is it important in cellular function?

Ribosomal protein L7 (RPL7) is a component of the large 60S ribosomal subunit and belongs to the Universal ribosomal protein uL30 family. It has a reported length of 248 amino acid residues in humans and a molecular weight of approximately 29.2 kDa, with subcellular localization primarily in the cytoplasm. RPL7 plays a critical role in protein synthesis as part of the ribosomal machinery that translates mRNA into protein. Additionally, it is widely expressed across multiple tissue types, suggesting its fundamental importance in cellular function. RPL7 can also be referred to by various synonyms including humL7-1, uL30, 60S ribosomal protein L7, large ribosomal subunit protein uL30, and simply L7 . The protein's conservation across species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken further underscores its evolutionary significance and essential cellular functions.

What applications are RPL7 antibodies most commonly used for?

RPL7 antibodies are utilized in multiple experimental applications with Western blotting (WB) being the most widely employed technique for detecting and quantifying RPL7 protein expression. The antibody demonstrates high specificity and sensitivity in Western blot applications with recommended dilutions typically ranging from 1:500 to 1:3000, depending on the specific antibody formulation and experimental conditions . Beyond Western blotting, RPL7 antibodies are frequently used in immunohistochemistry (IHC) with recommended dilutions of 1:20 to 1:200 for detecting the protein in tissue sections. Immunofluorescence (IF) and immunocytochemistry (ICC) applications are also common, with typical dilutions ranging from 1:50 to 1:500 . Additional applications include immunoprecipitation (IP), requiring approximately 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate, and RNA immunoprecipitation (RIP) for studying RNA-protein interactions involving RPL7. Enzyme-linked immunosorbent assay (ELISA) represents another useful application for quantitative detection of RPL7 .

What sample types are compatible with RPL7 antibodies?

RPL7 antibodies have demonstrated reactivity across multiple species, with validated compatibility for human, mouse, and rat samples . Positive Western blot detection has been specifically confirmed in human cell lines such as HEK-293 cells and in mouse kidney tissue. For immunoprecipitation protocols, HEK-293 cells have shown successful results. In immunohistochemistry applications, human skin cancer tissue has been validated for use with RPL7 antibodies, though specific antigen retrieval methods may be necessary for optimal results. Most commonly, antigen retrieval with TE buffer (pH 9.0) is recommended, although citrate buffer (pH 6.0) can serve as an alternative . For immunofluorescence and immunocytochemistry applications, HEK-293 cells have been confirmed as suitable samples. The cross-reactivity of RPL7 antibodies across these species makes them versatile tools for comparative studies examining ribosomal function and protein synthesis mechanisms in different model systems.

How should RPL7 antibody dilutions be optimized for Western blotting?

Optimization of RPL7 antibody dilutions for Western blotting requires systematic testing to establish the ideal balance between specific signal detection and background minimization. Begin with a dilution range based on manufacturer recommendations, typically starting at 1:500 to 1:3000 for RPL7 antibodies . Prepare a gradient of at least three different dilutions (e.g., 1:500, 1:1000, and 1:3000) using the same protein sample and identical Western blot conditions. When analyzing the resulting blots, evaluate both signal intensity at the expected molecular weight (29-30 kDa for RPL7) and non-specific background signals. The optimal dilution should produce a clear band at the expected molecular weight with minimal background. Factors that may influence optimal dilution include protein concentration in your samples, detection method (chemiluminescence, fluorescence, or colorimetric), and incubation conditions. For particularly challenging samples, consider extending primary antibody incubation to overnight at 4°C rather than 1-2 hours at room temperature. Additionally, blocking conditions may need adjustment—try different blocking agents (BSA vs. non-fat milk) if background issues persist. Once optimized, maintain consistent dilution ratios across experiments to ensure reproducibility and reliable quantitative comparisons .

What is the recommended protocol for immunohistochemistry with RPL7 antibodies?

For immunohistochemistry applications with RPL7 antibodies, begin with tissue fixation in 10% neutral buffered formalin followed by paraffin embedding using standard histological techniques. Cut sections to 4-6 μm thickness and mount on positively charged slides. Deparaffinize sections in xylene and rehydrate through a graded ethanol series. Antigen retrieval is critical for RPL7 detection—use TE buffer at pH 9.0 in a pressure cooker or water bath at 95-100°C for 15-20 minutes, although citrate buffer at pH 6.0 may serve as an alternative if needed . Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes, followed by protein blocking with 5% normal serum or commercial blocking solution for 30 minutes. Apply the primary RPL7 antibody at 1:20 to 1:200 dilution (start with the middle range and optimize as needed) and incubate in a humidified chamber overnight at 4°C or for 1 hour at room temperature . After washing with PBS or TBS buffer, apply an appropriate HRP-conjugated secondary antibody and incubate for 30 minutes at room temperature. Visualize with DAB substrate, counterstain with hematoxylin, dehydrate through ethanol series, clear in xylene, and mount with permanent mounting medium. For multiplex immunohistochemistry involving RPL7, carefully select antibodies raised in different host species to avoid cross-reactivity and consider using fluorescent detection systems with spectrally distinct fluorophores.

What controls should be included in experiments using RPL7 antibodies?

Rigorous experimental design with RPL7 antibodies necessitates multiple controls to ensure valid and interpretable results. Positive controls should include samples known to express RPL7, such as HEK-293 cells or mouse kidney tissue, which have been validated for RPL7 expression . Negative controls must address both primary and secondary antibody specificity. For primary antibody controls, include a sample incubated with antibody diluent alone (no primary antibody) while maintaining all other steps in the protocol. For more stringent validation, include absorption controls where the primary antibody is pre-incubated with excess purified RPL7 protein or immunizing peptide before application to the sample—specific binding should be drastically reduced or eliminated. Technical replicate controls help assess protocol consistency, while biological replicates (different samples of the same tissue/cell type) account for biological variation. For knockdown validation, samples from RPL7 siRNA/shRNA-treated cells provide the most definitive specificity control. In Western blotting applications, molecular weight markers confirm that the detected band appears at the expected size of 29-30 kDa . For immunohistochemistry or immunofluorescence, include isotype controls using non-specific antibodies of the same isotype, concentration, and host species to identify potential non-specific binding. Lastly, for studies examining relative expression levels, include housekeeping protein controls (such as GAPDH or β-actin) for normalization.

How can RPL7 antibodies be utilized in studying ribosome biogenesis defects?

RPL7 antibodies serve as powerful tools for investigating ribosome biogenesis defects by enabling both qualitative and quantitative assessment of ribosome assembly. Researchers can employ sucrose gradient ultracentrifugation combined with Western blotting using RPL7 antibodies to examine the distribution of RPL7 across different ribosomal assembly intermediates. Alterations in this distribution pattern may indicate defects in specific steps of ribosome biogenesis. Immunoprecipitation with RPL7 antibodies followed by mass spectrometry analysis can identify abnormal protein-protein interactions within the ribosomal assembly complex that might contribute to biogenesis defects. For spatial analysis, immunofluorescence using RPL7 antibodies can reveal abnormal nucleolar morphology or mislocalization of ribosomal components between nuclear and cytoplasmic compartments. In studying disease models associated with ribosomopathies, RPL7 antibodies can help quantify changes in total ribosome content or distribution patterns across cellular compartments. Additionally, researchers can combine RPL7 antibodies with antibodies against nucleolar stress markers (such as p53 or NPM1) to correlate ribosome biogenesis defects with cellular stress responses. For dynamic studies, pulse-chase experiments with metabolic labeling followed by immunoprecipitation with RPL7 antibodies can measure the kinetics of ribosome assembly under normal versus pathological conditions .

What are the considerations for using RPL7 antibodies in RNA immunoprecipitation (RIP) experiments?

RNA immunoprecipitation (RIP) using RPL7 antibodies requires careful optimization to effectively isolate and identify RNA species associated with RPL7 protein complexes. Begin by cross-linking RNA-protein complexes in living cells using formaldehyde (1-2%) or UV irradiation to preserve interactions prior to cell lysis. Select a lysis buffer that effectively solubilizes ribonucleoprotein complexes while maintaining their integrity—typically containing detergents like NP-40 or Triton X-100, protease inhibitors, and RNase inhibitors. Pre-clear the lysate with protein A/G beads to reduce non-specific binding before adding RPL7 antibody at approximately 2-4 μg per milliliter of lysate . Since RPL7 participates in extensive protein-RNA interactions within the ribosome, stringent washing conditions should be carefully calibrated to maintain specific interactions while removing background. Following immunoprecipitation, RNA can be extracted using TRIzol or similar reagents and analyzed by RT-PCR, RNA-Seq, or microarray. For validation of RIP results, include IgG control immunoprecipitations and input samples for comparison. To distinguish direct from indirect RNA interactions, consider combining RIP with CLIP (cross-linking and immunoprecipitation) approaches that utilize UV cross-linking to capture only direct protein-RNA contacts. When interpreting results, remember that RPL7 primarily associates with rRNAs as part of the ribosome, so enrichment of specific mRNAs may indicate specialized regulatory functions beyond its canonical role in translation .

How do post-translational modifications of RPL7 affect antibody detection?

Post-translational modifications (PTMs) of RPL7 can significantly impact antibody detection and must be carefully considered when interpreting experimental results. RPL7 undergoes various modifications including phosphorylation, ubiquitination, acetylation, and methylation, each potentially altering epitope accessibility or antibody binding affinity. Phosphorylation events, particularly those occurring within or near antibody epitopes, may either enhance or inhibit antibody recognition depending on the specific antibody clone and epitope location. Researchers should consult the antibody manufacturer regarding the specific immunogen sequence used to generate the antibody and whether it contains known PTM sites . When studying PTM-specific aspects of RPL7 biology, consider using PTM-specific antibodies that recognize only modified forms of RPL7. For comprehensive analysis, compare results from multiple antibody clones recognizing different RPL7 epitopes. Treatment of samples with phosphatases, deubiquitinases, or other PTM-removing enzymes prior to immunoblotting can help determine if signal variations result from modifications rather than expression differences. When discrepancies arise between antibody detection methods (e.g., between Western blot and immunohistochemistry results), consider whether different sample preparation methods might differentially preserve certain PTMs. Mass spectrometry analysis of immunoprecipitated RPL7 can identify the specific modification profile of the protein under your experimental conditions, providing context for antibody detection patterns and potentially explaining unexpected results in antibody-based assays .

How can researchers address non-specific binding when using RPL7 antibodies?

Non-specific binding with RPL7 antibodies can compromise experimental data and lead to misinterpretation of results, but several strategies can effectively mitigate this issue. First, optimize blocking conditions by testing different blocking agents (5% non-fat milk, 3-5% BSA, or commercial blocking buffers) and extending blocking time to 1-2 hours at room temperature or overnight at 4°C. For Western blotting applications, increase the number and duration of washing steps using buffers containing slightly higher detergent concentrations (0.1-0.2% Tween-20) to remove weakly bound antibodies. Titrating the primary antibody concentration is essential—start with the manufacturer's recommended dilution (typically 1:500-1:3000 for Western blot) and adjust based on signal-to-noise ratio . For immunohistochemistry or immunofluorescence, include an additional serum blocking step using serum from the same species as the secondary antibody. Pre-adsorption of the primary antibody with the immunizing peptide (if available) can confirm specificity, as this should eliminate specific binding while leaving non-specific interactions unchanged. Consider including detergents (0.1-0.3% Triton X-100) in antibody dilution buffers to reduce hydrophobic non-specific interactions. For particularly problematic samples, try switching to more specific detection methods—for instance, monoclonal antibodies often display higher specificity than polyclonal alternatives, though potentially at the cost of signal strength . Finally, when analyzing data, always compare the observed molecular weight of detected bands with the expected size of RPL7 (29-30 kDa), and consider Western blot techniques that enhance resolution in this range.

What factors contribute to inconsistent RPL7 antibody staining in immunohistochemistry?

Inconsistent RPL7 antibody staining in immunohistochemistry can result from multiple variables across sample preparation, processing, and detection steps. Fixation conditions significantly impact epitope preservation—overfixation can mask epitopes while underfixation may compromise tissue morphology. Standardize fixation protocols using 10% neutral buffered formalin for 24-48 hours depending on tissue thickness. Antigen retrieval methods critically affect RPL7 detection; for optimal results, use TE buffer at pH 9.0, though citrate buffer at pH 6.0 provides an alternative if needed . The duration and temperature of antigen retrieval should be precisely controlled; most protocols recommend 15-20 minutes at 95-100°C in a pressure cooker or microwave. Antibody concentration and incubation conditions significantly influence staining consistency—dilutions between 1:20 and 1:200 are typically recommended for RPL7 antibodies in IHC applications . Storage conditions of both tissue samples and antibodies can contribute to variability; avoid repeated freeze-thaw cycles of antibodies and store tissue blocks at room temperature in low-humidity environments. Batch effects between experiments can be minimized by processing all comparative samples simultaneously and including positive control tissues (such as human skin cancer tissue for RPL7) in each batch . Detection system sensitivity varies among methods—consider switching from conventional HRP-DAB systems to more sensitive detection methods like tyramide signal amplification for low-abundance targets. Finally, automated staining platforms typically provide better consistency than manual methods and should be considered for large-scale studies requiring precise quantitative comparisons.

How do antibodies against RPL7 compare with antibodies against other ribosomal proteins?

Antibodies against RPL7 and other ribosomal proteins exhibit important differences and similarities that researchers should consider when designing experiments investigating ribosomal biology. The following table presents a comparative analysis of commonly used ribosomal protein antibodies:

RPL7 antibodies offer advantages for studying the large ribosomal subunit and general protein synthesis, with demonstrated reactivity across human, mouse, and rat samples . Unlike some ribosomal proteins that participate extensively in extra-ribosomal functions, RPL7 primarily functions within the ribosome, making its antibodies reliable markers for ribosome biogenesis and function. When selecting between RPL7 and other ribosomal protein antibodies, consider whether your research questions focus on the large (60S) or small (40S) subunit, as this determines which markers are most appropriate. For comprehensive ribosome analysis, combining antibodies against components of both subunits (e.g., RPL7 and RPS6) provides more complete insights into ribosome biology than using either alone. Researchers should also consider the specific technical characteristics of each antibody, including validated applications, recommended dilutions, and cross-reactivity profiles, when designing multi-parameter analyses of ribosomal function .

What recent research breakthroughs have utilized RPL7 antibodies?

Recent research breakthroughs utilizing RPL7 antibodies have substantially expanded our understanding of ribosomal biology in both normal physiology and disease states. In cancer research, RPL7 antibodies have been instrumental in identifying altered ribosome biogenesis pathways that contribute to malignant transformation. Studies have employed RPL7 immunohistochemistry to demonstrate correlations between ribosomal protein expression patterns and clinical outcomes in various cancer types, including skin cancer . In neurodegenerative disease research, investigations utilizing RPL7 antibodies have revealed abnormal ribosome biogenesis and protein synthesis rates in models of Alzheimer's and Parkinson's diseases, highlighting potential mechanisms underlying neuronal dysfunction. Developmental biology studies have used RPL7 antibodies in conjunction with imaging techniques to map spatial and temporal dynamics of ribosome distribution during embryonic development, offering insights into translation-dependent developmental regulation. In the field of viral pathogenesis, researchers have employed RPL7 antibodies to investigate how viruses manipulate the host cell's translational machinery, demonstrating interactions between viral proteins and components of the host ribosome including RPL7. Immunoprecipitation experiments using RPL7 antibodies have identified novel protein-protein and protein-RNA interactions, expanding our understanding of noncanonical functions of ribosomal proteins beyond their structural roles in ribosomes. Notably, RNA immunoprecipitation (RIP) studies with RPL7 antibodies have uncovered unexpected associations between ribosomal proteins and specific mRNA subsets, suggesting specialized ribosomes might preferentially translate distinct mRNA populations . Collectively, these advances highlight the versatility of RPL7 antibodies as research tools across diverse biological disciplines, from fundamental molecular mechanisms to translational disease research.

How can RPL7 antibodies contribute to understanding specialized ribosomes?

RPL7 antibodies offer valuable tools for investigating the emerging concept of specialized ribosomes—heterogeneous ribosome populations that may preferentially translate specific mRNA subsets. By combining RPL7 antibodies with other ribosomal protein markers in multiplexed immunofluorescence or mass cytometry, researchers can identify and characterize ribosome subpopulations with distinct protein compositions in various cellular contexts. Subcellular fractionation followed by immunoblotting with RPL7 antibodies allows comparison of ribosome heterogeneity across different cellular compartments, potentially revealing specialized translation machinery dedicated to local protein synthesis in neuronal dendrites, axons, or other distally located cellular regions. Gradient fractionation of polysomes combined with RPL7 immunoblotting can distinguish mRNAs associated with different ribosome variants, particularly when coupled with RNA-sequencing approaches. Researchers can employ RPL7 antibodies in proximity ligation assays to detect interactions between RPL7 and tissue-specific or condition-specific ribosomal proteins or ribosome-associated factors that might confer specialized functions. Temporal analysis using RPL7 antibodies during cellular differentiation or stress responses can reveal dynamic changes in ribosome composition that correlate with translational reprogramming. Importantly, cross-linking immunoprecipitation (CLIP) protocols utilizing RPL7 antibodies enable identification of specific mRNAs directly associated with RPL7-containing ribosomes under various physiological or pathological conditions . For investigating potential post-translational modifications that might contribute to ribosome specialization, researchers can compare results using antibodies recognizing total RPL7 versus modification-specific antibodies. These approaches collectively provide mechanistic insights into how ribosome heterogeneity might contribute to translational control in development, tissue homeostasis, and disease states.